EHA 2024 – Clemens Wendtner
Clemens Wendtner provides insights on treatment selection in CLL, emphasizing key principles for first-line therapy and summarizes the recent GAIA/CLL13 data comparing venetoclax combinations with chemoimmunotherapy in fit untreated patients. Additionally, he discusses factors guiding treatment choices in relapsed/refractory CLL and highlights the benefits of BTK inhibitors in indolent lymphomas.
Here is the full EHA 2024 report.
More posts
Preface – EHA 2024
At the European Hematology Association (EHA) congress held in Madrid, Spain, and virtually from 13th–16th June 2024, world-leading experts from 150 countries presented cutting-edge research and clinical trials. This year, we witnessed significant advancements in the treatment of chronic lymphocytic leukemia (CLL).
